Active Not Recruiting INTERVENTIONAL NCT04908202

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Sponsor: Bristol-Myers Squibb

Conditions Psoriatic Arthritis

Interventions Deucravacitinib Placebo

Updated 29 times since 2021 Last updated: Apr 3, 2026 Started: Jul 13, 2021 Primary completion: Sep 5, 2024 Completion: Jun 10, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Psoriatic Arthritis, this trial is ongoing. The trial is conducted by Bristol-Myers Squibb and has accumulated 29 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

29 versions recorded

Apr 28, 2026 — Present [daily]

Active Not Recruiting

Phase: PHASE3 → None
Dec 2025 — Apr 2026 [monthly]

Active Not Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE3
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 24 earlier versions

Oct 2024 — Jul 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE3
May 2023 — Mar 2024 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE3
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE3
Apr 2022 — Jun 2022 [monthly]

Recruiting PHASE3
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE3
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE3
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE3
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE3
Oct 2021 — Dec 2021 [monthly]

Recruiting PHASE3
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE3

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Allen, United States , Amarillo, United States , Barranquilla, Colombia , Beckley, United States , Beijing, China , Bialystok, Poland , Bogotá, Colombia , Bogotá, Colombia , Boise, United States and 173 more locations